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Abstract
Background: Information on malignant pancreatic neuroendocrine neoplasms (pNENs) is mostly from
retrospective studies in highly selected patients. The aim of this prospective, multicentre study was to
assess treatment and outcomes of malignant pNENs in clinical practice.
Patients and methods: Consecutive patients with newly diagnosed, histologically-proven pNENs were
included and followed-up for 2 years. Tumours were defined as malignant when nodal or distant
metastases were present or invasion of extrapancreatic structures/organs was evident.
Results: A total of 140 patients with malignant pNENs were included. Ninety-eight patients (70.0%)
underwent a surgical resection (76 radical and 22 palliative). Other non-surgical treatments were used in
101 patients (72.1%): somatostatin analogues (n = 63), chemotherapy (n = 30), ablative treatments (n = 15)
and peptide-receptor radionuclide therapy (n = 14). No relationship was observed between the 2010 WHO
classification and type of treatment. A surgical resection was more often performed in incidentally
detected tumours located in the pancreas body tail. Two-year progression-free survival was 63.8%: 82%
after a radical resection, 44% after a palliative resection and 41% without a resection. A radical resection
and Ki67 proliferative index >5% and >10% were the only significant prognostic determinants in multi-
variate analysis.
Conclusions: A radical resection is the cornerstone treatment of malignant pNENs and represents,
together with Ki67 assessment, the most powerful prognostic factor for 2-year outcomes.
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Introduction
Pancreatic neuroendocrine neoplasms (pNENs) are rare and het-
erogeneous entities, ranging from small asymptomatic lesions to
highly malignant metastatic tumours. Although known to be
uncommon, knowledge of their real incidence remains limited,
and there is also a lack of data on the natural history of the disease,
the different treatments used and therapeutic outcomes.1,2
Whereas a complete surgical resection is thought to be the only
curative treatment for pNENs,3,4 many other treatments have been
proposed and are currently utilized in different stages of malig-
nant disease. These include medical therapy with somatostatin
analogues,5 chemotherapy,6 new biological drugs (such as
everolimus and sunitinib),7,8 peptide-receptor radionuclide
therapy (PRRT),9 ablative therapy of liver metastases (emboliza-
tion, chemoembolization and radiofrequency ablation),10 and pal-
liative surgical resection (debulking).11,12 However, available data
on the frequency of use of treatments and associated outcomes are
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limited, with evidence usually from specialized centres with highly
selected patients that cannot readily be applied to the more
general patient population.
To help address this lack of data, in 2004 the Italian Association
for the Study of the Pancreas (AISP) initiated a prospective, obser-
vational,multicentre study on the clinicopathological features and
management of pNENs. A total of 310 patients with newly diag-
nosed, histologically-proven pNENs were identified with data at
diagnosis having been previously reported.13 The present study
reports the different treatments utilized in the subgroup of 140
patients with malignant tumours and analyses middle-term
(2 years) outcomes associated with different clinicopathological
features and therapeutic options.
Patients and methods
All newly diagnosed adult patients with pNENs observed con-
secutively from June 2004 to March 2007 in the 24 participating
centres (listed in Appendix A1) were included in the study.
Criteria for recruitment, histological diagnosis and classi-
fication have been previously reported in detail.13 Tumours
were defined as malignant when nodal or distant metastases were
present or invasion of extrapancreatic structures/organs were
evident. The Ki67 proliferative index was expressed as a percent-
age based on the count of Ki67-positive cells in 2000 tumour cells
in areas with the highest immunostaining using the MIB1 anti-
body (DBA, Milan, Italy) and were stratified into three groups:
Ki67 < 2%, Ki67 2% and20% and Ki67 > 20%. Patients were
also categorized using Ki67 cut-off values of 5% and 10% accord-
ing to Scarpa et al.14 After inclusion, each patient was followed-up
for a minimum of 2 years, with clinical and biochemical evalua-
tions at 6-month intervals as well as a contrast-enhanced total
body CT scan in patients for whom disease progression was sus-
pected. The study had an observational non-interventional design
as each diagnostic investigation and medical or surgical treatment
was performed according to the current clinical practice of each
individual centre.
Parameters recorded at inclusion in the study and methods of
data recording have been previously described.13 A surgical resec-
tion was considered complete if neither a gross residual tumour
nor metastases were detectable at the end of the procedure
(radical resection); otherwise, a resection was considered to be
palliative. At each follow-up observation, the following data were
recorded: modifications in symptoms, biochemical data, imaging
data, variations in medical treatment, new surgical treatments,
other new treatments and disease status (disease-free, stable
residual disease and disease progression). Progression was defined
according to RECIST criteria.15Death of the patient and cause of
death were recorded. Data were collected and tabulated centrally.
During the study period, a careful monitoring process was imple-
mented and at the end of the study additional quality control
(concerning completeness and congruence of each chart) was per-
formed. The study was approved by the Ethical Committee of each
participating centre and informed consent was obtained from all
patients.
Statistical analysis
Data are presented as median, mean, standard deviation (SD) and
95% confidence intervals (95% CI). Additional statistical tests
(Student’s t-test, chi-squared test, Pearson’s test, Fisher’s exact
test, the Levene test and anova) were utilized when appropriate.
Relationships between the variables were tested using regression
analysis. The difference was considered significant for a P-value <
0.05. Statistical analysis was performed using SPSS software
version 10 (SPSS Inc., Chicago, IL, USA). Parameters were
included in multivariate analysis if statistically significant at uni-
variate analysis, with a P-value less than 0.05.
Results
A total of 310 patients with pNENs were eligible for study inclu-
sion. Twenty-seven patients (8.7%) were lost at follow-up and
were excluded from the study. Of the 283 remaining, 140 (49.5%)
had pNENs classified as malignant and were included in this
analysis.
There were 77 males (55%) and 63 females (45%). The mean
age was 58.7 14.4 years, with the largest proportion in the 50–59
years age range (37.1%). Clinicopathological features are reported
in Table 1: only 16 patients (11.4%) had functioning pNENs,
which were as a result of gastrin production (n = 8), excess insulin
production (n = 3) or other hormones (glucagonoma, n = 2;
somatostatinoma, n = 2; ACTH-producing tumour, n = 1). In
symptomatic patients, the main symptoms reported were pain
(n = 47, 37.9%), weight loss (n = 27, 21.8%) and jaundice (n = 21,
16.9%). The body tail of the pancreas was the most frequent site of
the tumour (n = 81, 57.8%). According to the 2010 WHO classi-
fication,16 the majority of patients were classified as NET-G2 (n =
57, 40.7%), whereas according to TNM classification (UICC-
WHO)16,17 more than half were classified as having stage IV disease
(n = 80, 57.1%).
A surgical resection represented the most frequent treatment:
76 patients (54.3%) underwent a radical resection and 22 under-
went a palliative resection (15.7%). The type of radical resection
was pancreatoduodenectomy in 27 patients (35.5%), distal pan-
createctomy in 41 patients (53.9%), total pancreatectomy in 5
patients (6.6%) and middle pancreatectomy in 3 patients (3.9%).
A palliative resection was done by pancreatoduodenectomy (n =
8, 36.4%) or distal pancreatectomy (n = 14, 63.6%). Nine patients
(11.8%) undergoing a radical resection and 13 (59.1%) under-
going a palliative resection also underwent a liver resection.
Forty-two patients (30%) had no resection of the tumour,
although 12 of these underwent non-resective surgery (explora-
tory laparotomy in 11 patients and a by-pass procedure in one
patient).
A total of 101 patients (72.1%) received other non-surgical
treatments; some patients received more than one treatment
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(Table 1). The distribution of treatments according to the type of
surgery (radical resection, palliative resection and no resection) is
shown in Table 2.
At 2-year follow-up, 62 patients (44.3%) were disease free, 25
had stable residual disease (17.8%) and 21 had progressive disease
(15.0%). Thirty-two patients (22.8%) died from their disease
during follow-up. The median follow-up was 20.9 months.
Overall, 2-year progression-free survival (PFS) was 63.8% (Fig. 1).
Patients were divided into three groups according to the 2010
WHO classification (Table 1). The type of surgical treatment was
Table 1 Demographic characteristics, clinicopathological features and treatments performed in 140 patients with malignant pancreatic
neuroendocrine tumours, overall and according to the 2010 WHO classification16
Characteristic Overall (n = 140) NET-G1 (n = 40) NET-G2 (n = 57) NEC-G3 (n = 34) P-value
Male 77 (55.0%) 21 31 22 0.533
Age (mean), years 58.7 57.1 58.3 59.1 0.771
Non-functioning 124 (88.6%) 33 49 33 0.124
Symptomatic 81 (57.8%) 20 28 24 0.104
Primary tumour diameter (mean), mm 42.5 36.7 45.9 41.6 0.023
Lymph node metastases 89 (63.6%) 30 28 28 0.002
Hepatic metastases 66 (47.1%) 16 31 16 0.384
Radical resection 76 (54.3%) 22 32 18 0.974
Palliative resection 22 (15.7%) 6 11 5 0.871
No resection 40 (30.0%) 12 14 11 0.922
Liver resection 22 (15.7%) 5 10 7 0.683
Somatostatin analogues 63 (45.0%) 20 32 11 0.091
PRRT 14 (10.0%) 3 6 4 0.781
Ablative treatments 15 (10.7%) 4 6 4 1.000
Chemotherapy 30 (21.4%) 1 13 14 0.002
Nine patients were not classified because grading assessment was not available. Bold indicates significant P-value.
PRRT, peptide receptor radio therapy
Table 2 Demographic characteristics, clinicopathological features and treatments performed in 140 patients with malignant pancreatic
neuroendocrine tumours undergoing a radical resection (group A), palliative resection (group B) or without resection (group C)
Characteristic Group A
(n = 76)
Group B
(n = 22)
Group C
(n = 42)
P-value
Male 40 12 25 0.797
Age (mean), years 56.9 62.7 60.6 0.840
Non-functioning 67 17 40 0.095
Symptomatic 34 12 35 0.000
Primary tumour diameter (mean), mm 43.4 45.0 42.1 0.018
Tumour site:
Pancreatic head 25 8 19 0.048
Pancreatic body-tail 46 14 21 0.234
Pancreatic diffuse 5 0 2 (*)
Lymph node metastases 47 15 27 0.861
Hepatic metastases 9 21 36 0.000
Liver resection 9 13 0 0.000
Somatostatin analogues 19 18 26 0.408
PRRT 2 1 11 (*)
Ablative treatments 3 8 4 (*)
Chemotherapy 13 2 15 0.042
(*) not applicable due to the small numbers. Bold indicates significant P-value.
PRRT, peptide receptor radio therapy.
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the same across the three groups, as were non-surgical treatments
with the exception of more frequent use of chemotherapy in
NEC-G3 patients. As expected, the prognosis was correlated
with the stage of the neoplasm: in Fig. 2, PFS curves according
to the 2010 WHO classification are reported, confirming a signi-
ficant correlation between survival and stage of the neoplasm
(P < 0.001).
Patients were also divided according to the type of surgical
treatment received: a radical resection (group A), a palliative
resection (group B) or no surgical resection (group C); clinico-
pathological features and other treatments performed are
reported in Table 2. Figure 3 shows PFS curves of patients divided
by type of surgical procedure, confirming a significant better
2-year survival for patients undergoing a radical resection (P <
Figure 1 Overall progression-free survival curve of 140 patients with a malignant pancreatic neuroendocrine tumour
Figure 2 Progression-free survival curves of 131 patients with a malignant pancreatic neuroendocrine tumour, according to the 2010 WHO
classification (40 NET G1, 57 NET G2, 34 NEC G3). (NET G1 versus NET G2: P = 0.155; NET G1 versus NEC G3: 0.000)
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0.0001). Among patients undergoing a palliative resection, sur-
vival was significantly correlated with Ki67 values: in particular, 14
patients with a Ki67 value 5% had a 2-year PFS of 54% com-
pared with 18% in 8 patients with Ki67 values > 5% (P < 0.001).
Thirteen patients with concomitant liver resection had a slightly
worse 2-year PFS than 9 patients without liver resection, although
this was not significant (35% versus 58%, P = 0.168).
In univariate analysis, poor histological differentiation, Ki67
values > 5%, Ki67 values > 10%, the presence of symptoms, liver
or lymph node metastases and a non-radical resection were sig-
nificantly correlated with poor 2-year PFS (Table 3). In multivari-
ate analysis, a radical resection and Ki67 values > 5% or > 10%
were significantly correlated with overall survival (OS), whereas a
radical resection was the only parameter significantly correlated
with PFS (Table 4).
Discussion
Information on pNENs is mostly derived from small, retrospec-
tive, uncontrolled studies conducted on highly selected patients.
The present data offer the advantage of including a non-selected
group of patients diagnosed with malignant pNENs, and repre-
sents a true picture of current therapeutic practice in Italy, espe-
cially considering that the study enrolled about one-quarter of
cases expected in the entire country.13 This prospective, multicen-
tre analysis confirms that a surgical resection, when feasible,
should be the cornerstone of treatment in this cohort. In addition,
a radical resection represents the most significant prognostic
factor for both increased PFS and OS.
The present analysis was limited to patients with malignant
disease, although the distinction between benign and malignant
pNENs is quite complex and controversial as shown by the several
classification systems proposed in recent years.16–18 For clinically
benign pNENs, surgery without the requirement for additional
treatments is standard practice with the choice of surgical proce-
dure usually the main clinical decision.19 In comparison, the clini-
calmanagement of malignant pNENs ismuchmore complex,with
a range of different surgical and non-surgical therapies thatmay be
used in combination and/or at different disease stages.20At present,
there are no clear guidelines or recommendations on the best
treatment strategy to beused.The choice of treatment often reflects
the specific clinical experience and competence of the clinician
and/or centre, rather than being based on the best clinical evidence.
The present study provides information on the type of treat-
ments performed in patients with malignant pNENs in the first 2
years after diagnosis and show that a surgical resection remains by
far the most frequently performed treatment. General agreement
exists that complete removal of the tumour should be the first-line
therapeutic approach whenever technically feasible21 and the
present data confirm this attitude.
The role of palliative surgery is under debate,11,22–25 with recent
data failing to show any survival advantage after a primary
tumour resection in the presence of liver metastases26 and the
European NeuroEndocrine Tumor Society’s (ENETS) guidelines
do not recommend debulking for unresectable primary
NF-pNENs.4 In the present series, the main reason for a non-
radical resection was the presence of hepatic metastases. Results
after a palliative resection in this study are unsatisfactory, with a
Figure 3 Progression-free survival curves of 140 patients with a malignant pancreatic neuroendocrine tumour undergoing a radical resection
(76 patients), palliative resection (22 patients) or no resection (42 patients). Radical resection versus no resection: P = 0.000; palliative
resection versus no resection: P = 0.868
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2-year PFS rate significantly worse than that observed after a
radical resection and similar to that of patients without a resec-
tion. Moreover, no survival advantage was observed in the sub-
group of palliative resection patients with concomitant liver
resection. This confirms the limited therapeutic benefit of pallia-
tive surgery in malignant pNENs. However, it should be noted
that the 2-year prognosis of the subgroup of patients with a Ki67
proliferative index < 5% was considered satisfactory, suggesting
that palliative surgery can be considered a possible option in
selected patients who have pre-operative assessment of disease
grade.26
It is interesting to observe that the decision to perform surgery
or not and the possibility of achieving a radical resection did not
correlate with the degree of differentiation of the neoplasm
according to 2010 WHO classification. To some degree this
finding is not surprising, as very limited information on tumour
differentiation is available before surgery and the decision to
operate is often still based on morphological rather than biologi-
cal findings. In the present series, neoplasms not treated by resec-
tion were more frequently non-functioning and located in the
head of the pancreas: the greater complexity of a pancreatoduo-
denectomy compared with a distal pancreatectomy probably
accounts for the lower number of resections performed when the
tumour was located in the head of the gland. Other than the rate
of hepatic metastases, no different clinicopathological character-
istics were observed between patients undergoing radical or pal-
liative surgery.
The majority of patients undergoing surgery also received other
treatments. This included almost all of those undergoing palliative
surgery, but also about 40% of those who underwent a radical
resection. In some patients these treatments were to treat disease
recurrence after resection, but in other patients were administered
with adjuvant intent, an indication currently not recom-
mended.5,21 The most frequent additional treatment was the use of
somatostatin analogues; these were administered irrespective of
the tumour proliferation index and confirms the widespread use
of these agents, consistent with their good safety profile and recent
demonstration of efficacy.5,27 Ablative treatments were performed
in just over one-third of patients undergoing palliative surgery,
highlighting the greater importance attributed to liver-directed
treatments for disease control after primary removal. PRRT had a
Table 3 Univariate analysis for 2-year progression-free survival
Variables Hazard ratio (95% CI) P
Radical resection
No 1.0
Yes 0.23 (0.12–0.55) 0.000
Histology
Well differentiated 1.0
Poorly differentiated 6.3 (3.08–12.98) 0.000
Tumour site
Body-tail 1.0
Head 1.07 (2.08–12.98) 0.864
Hormonal syndrome
No 1.0
Yes 0.26 (0.03–1.78) 0.186
Presence of symptoms
No 1.0
Yes 3.4 (1.45–8.66) 0.006
Ki 67 values
<2% 1.0
3–5% 5.1 (0.58–46.49) 0.147
6–10% 21.3 (2.69–177.86) 0.004
>10% 28.5 (3.88–220.14) 0.001
Lymph node metastases
No 1.0
Yes 2.6 (1.06–6.35) 0.033
Hepatic metastases
No 1.0
Yes 3.8 (1.65–8.30) 0.001
Somatostatin analogues
No 1.0
Yes 1.0 (0.48–1.98) 0.995
Chemotherapy
No 1.0
Yes 1.8 (0.48–3.57) 0.116
PRRT
No 1.0
Yes 0.7 (0.27–1.86) 0.540
Ablative treatments
No 1.0
Yes 0.9 (0.32–2.64) 0.974
PRRT, peptide receptor radio therapy. Bold indicates significant P value.
Table 4 Cox multivariate analysis for overall and progression-free
survival
Variable Hazard risk 95% CI P
Overall survival
Radical resection 0.04 0.004;0.4 0.0060
Ki67 > 5% 7.4 1.95;28.2 0.0020
Ki67 > 10% 50.3 4.4;573.7 0.0020
Progression-free survival
Radical resection 0.2 0.056;0.71 0.0130
Variables included in the regression model: gender (male versus female),
age (<40 versus 41–50 versus 51–60 versus 61–70 versus > 70 years),
resection (radical versus palliative versus no resection), histology (well
differentiated versus poorly differentiated), tumour site (head versus
body-tail), hormonal syndrome (yes versus no), presence of symptoms
(yes versus no), Ki67 values (<2% versus 3–5% versus 6–10% versus >
10%), lymph node metastases (yes versus no), hepatic metastases (yes
versus no), treatment with somatostatin analogues (yes versus no), treat-
ment with chemotherapy (yes versus no), PRRT (yes versus no) and
ablative treatments (yes versus no).
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limited application, probably reflecting the lack of comparative
studies and definite application criteria for this option.28
Whereas the degree of differentiation of the tumour was not
correlated with the surgical choice, it correlates with the choice of
medical treatments, in particular chemotherapy. This is in accord-
ance with recent guidelines29 and confirms the key role of Ki67
assessment in planning the multidisciplinary treatment of
pNENs.
The overall prognosis of patients with a malignant pNEN was
confirmed to be quite good, with a 64% 2-year PFS that is in
accordance with other reports.1,30,31 As recently underlined,32 it is
important to consider PFS instead of survival in the prognostic
evaluation of pNENs, because of the observed long survival period
after progression in many patients. Radical resection was con-
firmed to be the most powerful prognostic determinant, not only
for OS but also for PFS: this finding is well known and has been
previously reported.3,4,12,21 One possible criticism of this finding is
that radical surgery was simply a surrogate for less advanced
disease, as patients who did not undergo a radical resection were
typically those with liver metastases. As such, the presence of liver
metastasesmay be the determining factor in the duration of PFS or
OS, rather than whether patients underwent a radical resection or
not. To investigate this more fully, it would be necessary for long-
term follow-up radical surgery patients to see how many develop
liver or distant metastases and the impact of this on survival. The
2010WHO staging classification proved to be a significant tool for
predicting survival between well and poorly differentiated pNENs,
but was less useful in differentiating betweenNETG1 andNETG2
patients, as has been previously reported.14 In this regard, it is
important to observe that a Ki67 cut-off value of 5% is confirmed
as a significant prognostic determinant in both univariate and
multivariate analysis.33 The possible introduction of a cut-off of
5%, either instead of or together with the 2% cut-off value cur-
rently used, could usefully be included in the ongoing considera-
tions to improveTNMstaging systems for pNENs.31 This especially
so given that the current grading system is more general and
intended for NENs at all anatomical sites of the gastroenteropan-
creatic tract.14 Non-surgical treatments were not prognostic deter-
minants in our series, although this is not surprising given the small
numbers of patients receiving these treatments and the short
period of follow-up.
Limitations of this study include the heterogeneity of treat-
ments performed and the absence of defined inclusion criteria to
decide therapeutic choices. In addition, imaging evaluation
during the follow-up period was not standardized across centres.
However, these study weaknesses are frequently seen in other
clinical series assessing the outcome of malignant pNENs; the
rarity and clinical heterogeneity of these tumours has prevented
large, randomized, controlled trials aimed at evaluating the spe-
cific role of single treatment modalities.
In conclusion, the present study highlights that a radical surgi-
cal resection, when feasible, represents the first-choice treatment
for malignant pNENs, offering the best chance for extended PFS.
As such, it should be considered for every patient with a pNEN.
Somatostatin analogues are the most frequently administered
non-surgical treatment, with liver-directed therapies often per-
formed in patients with liver metastases. Staging of the tumour,
according to the 2010 WHO classification, is significantly corre-
lated with PFS, whereas the Ki67 proliferation index is a powerful
prognostic indicator, especially if 5% or 10% cut-off values are
chosen.
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Appendix A1
Members of the AISP-Network Study Group
Investigator Center City
Di Carlo Valerio OSPEDALE S. RAFFAELE Milano
Pederzoli Paolo AZIENDA OSPEDALIERA VERONA (POLICLINICO) Verona
Delle Fave Gianfranco AZIENDA OSPEDALE POLICLINICO S. ANDREA Roma
Pedrazzoli Sergio AZIENDA OSPEDALIERA DI PADOVA Padova
Tomassetti Paola AZIENDA OSPEDALIERA POLICLINICO S. ORSOLA – MALPIGHI Bologna
Garcea Domenico OSPEDALE PIERANTONI Forlì
Uomo Generoso AZIENDA OSPEDALIERA ‘A. CARDARELLI’ Napoli
Colangelo Ettore OSPEDALE CIVILE Pescara
Mosca Franco OSPEDALE CISANELLO Pisa
Fronda Gian Ruggero OSPEDALE S. GIOVANNI BATTISTA MOLINETTE Torino
Bresadola Fabrizio POLICLINICO UNIVERSITARIO A GESTIONE DIRETTA Udine
Cantore Maurizio OSPEDALE CIVILE Carrara
Leone Biagio Eugenio OSPEDALE S. GERARDO Monza
Farinati Fabio AZIENDA OSPEDALIERA DI PADOVA Padova
Toma Sandro Salvatore OSPEDALE CASA SOLLIEVO DELLA SOFFERENZA San Giovanni Rotondo
Luppi Gabriele AZIENDA OSPEDALIERA POLICLINICO Modena
Bene Anna AZIENDA POLICLINICO UNIVERSITARIO Messina
Bajetta Emilio ISTITUTO NAZIONALE PER CURA TUMORI Milano
Ruffini Livia AZIENDA OSPEDALIERA G. BROTZU Cagliari
Gebbia Vittorio CLINICA MADDALENA Palermo
Liguori Luciano OSPEDALE BELLARIA Bologna
De Toma Giorgio AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I Roma
Dogliotti Luigi AZIENDA SANITARIA OSPEDALIERA ‘S. LUIGI’ Orbassano
Massidda Bruno POLICLINICO UNIVERSITARIO Cagliari
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